Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer

Journal of Clinical Oncology

Volumn 19, Issue 2, 2001, Pages 584-592

  Rudek, M A ^a   Figg, W D ^a   Dyer, V ^a   Dahut, W ^a   Turner, M L ^a   Steinberg, S M ^a   Liewehr, D J ^a   Kohler, D R ^a   Pluda, J M ^a   Reed, E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; BASIC FIBROBLAST GROWTH FACTOR; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; SUNSCREEN; VASCULOTROPIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HEARTBURN; HUMAN; LIVER TOXICITY; LUPUS ERYTHEMATOSUS; MALE; METASTASIS; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PHOTOTOXICITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SOLID TUMOR; TREATMENT OUTCOME;

EID: 0035863463     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.2.584     Document Type: Article

References (41)

1. Metalloproteinases and cancer invasion
2. Changing views of the role of matrix metalloproteinases in metastasis
3. Minocycline reduces gingival collagenolytic activity during diabetes: Preliminary observations and a proposed new mechanism of action
4. Tetracyclines inhibit tissue collagenase activity: A new mechanism in the treatment of periodontal disease
5. Tetracyclines inhibit tissue collagenases: Effects of ingested low-dose and local delivery systems
6. Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources
7. Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs
8. Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells
9. Reactive oxygen species activate and tetracyclines inhibit rat osteoblast collagenase
10. Procollagenase is reduced to inactive fragments upon activation in the presence of doxycycline
11. Activation of recombinant human neutrophil procollagenase in the presence of doxycycline results in fragmentation of the enzyme and loss of enzyme activity
12. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis
13. Tetracycline-based MMP: Inhibitors can prevent fibroblast-mediated collagen gel contraction in vitro
14. Potential application of a chemically modified non-antimicrobial tetracycline (CMT-3) against metastatic prostate cancer
15. Chemically modified non-antimicrobial tetracyclines inhibit activity of phospholipases A2
16. Chemically modified tetracyclines inhibit inducible nitric oxide synthase expression and nitric oxide production in cultured rat mesangial cells
17. Tetracycline derivatives induce apoptosis selectively in cultured monocytes and macrophages but not in mesenchymal cells
18. High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasma
19. Accelerated titration designs for phase I clinical trials in oncology
20. Drug-induced lupus erythematous associated with COL-3
21. Seminars in medicine of the Beth Israel Hospital. Boston: Clinical applications of research on angiogenesis
22. Phototoxic eruptions due to doxycycline: A dose-related phenomenon
23. Oxidation photosensitized by tetracyclines
24. Mechanism of tetracycline phototoxicity
25. Singlet molecular oxygen-mediated photo-oxidation of tetracyclines: Kinetics, mechanism and microbiological implications
26. Comparative safety of tetracycline, minocycline, and doxycycline
27. Sideroblastic anemia in man: Observations on seventy cases
28. Effect of chloramphenicol on erythropoiesis
29. Antituberculous drugs and sideroblastic anemia
30. Abnormal ("ringed") sideroblasts in various hematologic and non-hematologic disorders
31. Pharmacokinetics and bioavailability of doxycycline in humans
32. Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects
33. Comparative pharmacokinetics of doxycycline and oxytetracycline in patients with hyperlipidemia
34. Demethylchlortetracycline: A new tetracycline antibiotic that yields greater and more sensitive antibacterial activity
35. A study of the interaction between oxytetracycline and pyridostigmine
36. Influence of ethanol ingestion on tetracycline kinetics
37. Pharmacokinetics of lymecycline and doxycycline in serum and suction blister fluid
38. Clinical pharmacologic studies with minocycline
39. Influence of repetitive dosing of tetracyclines on biologic half-life in serum
40. Comparative serum binding, distribution and excretion of tetracycline and a new analogue, methacycline